Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure

Authors: Abecasis A, Cabanas J, Camacho RJ, Gomes P, Libin P, Theys K, Van Laethem K
Publication Year: 2015
Journal: Journal of Clinical Virology
Link: http://www.ncbi.nlm.nih.gov/pubmed/26305833

BACKGROUND: Dolutegravir is approved for the treatment of HIV-1 patients exposed to other integrase inhibitors, but the decision to use dolutegravir in this setting should be informed by drug resistance testing. OBJECTIVES: This study determined the extent of disagreement in predicted residual dolutegravir activity after raltegravir use, and identified individual mutational patterns for which uncertainty […]
Read More

Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine

Authors: Camacho RJ, Gomes P, Portuguese HIVRSG, Rhee SY, Theys K, Vandamme AM
Publication Year: 2015
Journal: Clinical Microbiology and Infection
Link: http://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(15)00299-2/fulltext%20

Rilpivirine is a second-generation nonnucleoside reverse-transcriptase inhibitor (NNRTI) currently indicated for first-line therapy, but its clinical benefit for HIV-1 infected patients failing first-generation NNRTIs is largely undefined. This study quantified the extent of genotypic rilpivirine resistance in viral isolates from 1212 patients upon failure of efavirenz- or nevirapine-containing antiretroviral treatment, of whom more than respectively […]
Read More

HIV-2 Integrase Polymorphisms and Longitudinal Genotypic Analysis of HIV-2 Infected Patients Failing a Raltegravir-Containing Regimen

Authors: Abecasis A, Aguas MJ, Almeida I, Camacho RJ, Cavaco-Silva J, Cunha C, Diniz A, Germano I, Gomes P, Gonçalves Mde F, Maltez F, Miranda AC, Narciso J, Poças J, Portuguese HIV-2 Resistance Study Group
Publication Year: 2014
Journal: PLoS One
Link: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0092747

To characterize the HIV-2 integrase gene polymorphisms and the pathways to resistance of HIV-2 patients failing a raltegravir-containing regimen, we studied 63 integrase strand transfer inhibitors (INSTI)-naïve patients, and 10 heavily pretreated patients exhibiting virological failure while receiving a salvage raltegravir-containing regimen.
Read More

Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure

Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine

HIV-2 Integrase Polymorphisms and Longitudinal Genotypic Analysis of HIV-2 Infected Patients Failing a Raltegravir-Containing Regimen

About GHTM

Contacts

Funding